AHA GUIDELINES Bundle (free trial)

Diagnosis and Management of Aortic Disease

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1483260

Contents of this Issue

Navigation

Page 83 of 97

84 Treatment Start GC 40–60 mg/d and go directly to Phase II Continue taper Phase I Phase II Taper GC (to 0 mg at 6 mo with Tocilizumab) Target achieved? Consult expert center Start Tocilizumab (or Methotrexate) Risk for or presence of glucocorticoid-related adverse events Taper tocilizumab or methotrexate YES YES NO Figure 25. The 2018 European Alliance of Associations for Rheumatology (EULAR; Formerly European League Against Rheumatism) Recommended Algorithms for the Pharmacological Treatment of Giant Cell Arteritis

Articles in this issue

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - Diagnosis and Management of Aortic Disease